Fresenius SE & Co. KGaA (0OO9.IL)

27.22 -0.13 (-0.48%) As of 03:22PM BST. Market open.

Fresenius SE & Co. KGaA

Else-Kroener-Strasse 1
Bad Homburg vor der Höhe 61352
Germany
49 6172 6080
https://www.fresenius.com

Sector(s): Healthcare
Industry: Medical Care Facilities
Full-time employees: 315,233

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael Sen	CEO, Pres & Chairman of Management Board - Fresenius Management SE	2.91M	N/A	1968
Ms. Sara Lisa Hennicken	CFO & Member of the Management Board - Fresenius Management SE	919k	N/A	1980
Dr. Sebastian Biedenkopf	Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board	1.51M	N/A	1964
Ms. Helen Giza	Member of the Management Board - Fresenius Management SE	1.98M	N/A	1968
Mr. Pierluigi Antonelli	Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi	N/A	N/A	N/A
Dr. Michael Sven Moser Ph.D.	Member of Management Board of Fresenius Management SE	N/A	N/A	1977
Mr. Robert Moller	Member of the Management Board of Fresenius Management SE	N/A	N/A	1970
Mr. Markus Georgi	Sr. VP of Investor Relations	N/A	N/A	N/A
Matthias Link	Sr. VP Corp. Communications	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Corporate governance

Fresenius SE & Co. KGaA’s ISS governance QualityScore as of 1 October 2023 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.